Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:monofluorobenzene
go back to main search page
Accession:CHEBI:5115 term browser browse the term
Definition:The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.
Synonyms:related_synonym: Fluorbenzol;   Fluorobenzene;   Formula=C6H5F;   InChI=1S/C6H5F/c7-6-4-2-1-3-5-6/h1-5H;   InChIKey=PYLWMHQQBFSUBP-UHFFFAOYSA-N;   SMILES=Fc1ccccc1;   phenyl fluoride
 xref: Beilstein:1236623;   CAS:462-06-6;   Gmelin:49856;   KEGG:C11272;   PMID:22976426;   PMID:24060903;   Patent:CN101224914;   Patent:US4390740;   Reaxys:1236623;   Wikipedia:Fluorobenzene


show annotations for term's descendants           Sort by:
lapatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO lapatinib results in decreased activity of ABCB11 protein CTD PMID:20829430 PMID:23956101 PMID:28437613 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO lapatinib inhibits the reaction [ABCB1 protein results in increased export of and results in decreased susceptibility to Doxorubicin]; lapatinib inhibits the reaction [azidoprazosin binds to ABCB1 protein]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] CTD PMID:18829547 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO lapatinib results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO lapatinib inhibits the reaction [ABCG2 gene mutant form results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Topotecan]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; lapatinib inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]; lapatinib inhibits the reaction [azidoprazosin binds to ABCG2 protein]; lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate] CTD PMID:18829547 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein] CTD PMID:26643609 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases activity
decreases phosphorylation		 ISO [Bortezomib co-treated with Lapatinib] results in decreased phosphorylation of AKT1 protein; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of AKT1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
lapatinib results in decreased expression of AKT1 protein; lapatinib results in decreased expression of AKT1 protein modified form
lapatinib results in decreased activity of AKT1 protein
Lapatinib results in decreased phosphorylation of AKT1 protein		 CTD PMID:15665275 PMID:16091755 PMID:19435893 PMID:19509167 PMID:20701607 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ALDH1A1 protein CTD PMID:26643609 NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 ISO Lapatinib results in increased expression of BAX protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased expression of BAX protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]]		 CTD PMID:29387217 PMID:32890875 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions		 ISO Lapatinib results in decreased expression of BCL2 protein
AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]		 CTD PMID:29387217 PMID:32890875 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO lapatinib results in decreased expression of BIRC5 protein CTD PMID:16091755 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA] CTD PMID:25981168 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Casp3 caspase 3 increases cleavage
increases activity
multiple interactions		 ISO Lapatinib results in increased cleavage of CASP3 protein
Lapatinib results in increased activity of CASP3 protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP3 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]		 CTD PMID:29387217 PMID:32890875 PMID:37788138 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp7 caspase 7 increases activity ISO Lapatinib results in increased activity of CASP7 protein CTD PMID:37788138 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity
increases cleavage		 ISO 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP9 protein]
Lapatinib results in increased activity of CASP9 protein		 CTD PMID:29387217 PMID:37788138 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ccna2 cyclin A2 decreases expression ISO lapatinib results in decreased expression of CCNA2 protein CTD PMID:25221644 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression		 ISO [afimoxifene co-treated with Lapatinib] results in decreased expression of CCND1 protein; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]
lapatinib results in decreased expression of CCND1 protein		 CTD PMID:15665275 PMID:25221644 PMID:32890875 PMID:33396024 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] CTD PMID:15665275 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Cd24 CD24 molecule multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in decreased expression of CD24 protein CTD PMID:26643609 NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662 		JBrowse link
G Cd44 CD44 molecule multiple interactions ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CD44 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]] CTD PMID:26643609 PMID:33396024 NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620 		JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO [Genistein co-treated with Lapatinib] promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein] CTD PMID:26643609 PMID:32890875 PMID:33396024 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein] CTD PMID:26643609 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions ISO [afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] CTD PMID:15665275 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] CTD PMID:32890875 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression		 ISO [afimoxifene co-treated with Lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; [afimoxifene co-treated with Lapatinib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]
lapatinib results in increased expression of CDKN1B protein		 CTD PMID:15665275 PMID:20701607 PMID:32890875 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity
increases metabolic processing		 ISO Lapatinib results in decreased activity of CYP1A1 protein
CYP1A1 protein results in increased metabolism of Lapatinib		 CTD PMID:33814510 PMID:37788138 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Lapatinib results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing
multiple interactions		 ISO CYP3A4 protein results in increased metabolism of Lapatinib
[CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of HMOX1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of NQO1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD2 mRNA		 CTD PMID:26958860 PMID:33259822 PMID:37788138 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases metabolic processing
multiple interactions		 ISO CYP3A5 protein results in increased metabolism of Lapatinib
[CYP3A5 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]		 CTD PMID:26958860 PMID:37788138 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Egfr epidermal growth factor receptor decreases activity
affects response to substance
multiple interactions		 ISO lapatinib results in decreased activity of EGFR protein
EGFR protein affects the susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]; lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]		 CTD PMID:15665275 PMID:17192538 PMID:19509167 PMID:20549698 PMID:28739874 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation
decreases expression
decreases activity		 ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein; Bortezomib promotes the reaction [Lapatinib results in decreased phosphorylation of ERBB2 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of MCM7 protein]; Lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]
lapatinib results in decreased phosphorylation of ERBB2 protein
lapatinib results in decreased expression of ERBB2 protein
lapatinib results in decreased activity of ERBB2 protein		 CTD PMID:15665275 PMID:16091755 PMID:17192538 PMID:19509167 PMID:20197467 More... NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 decreases expression
decreases activity		 ISO lapatinib results in decreased expression of ERBB3 protein modified form
lapatinib results in decreased activity of ERBB3 protein		 CTD PMID:19435893 PMID:19509167 NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525 		JBrowse link
G Esr1 estrogen receptor 1 decreases activity
multiple interactions		 ISO lapatinib results in decreased activity of ESR1 protein
[lapatinib co-treated with afimoxifene] results in decreased activity of ESR1 protein		 CTD PMID:15665275 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Lapatinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions		 ISO Lapatinib results in increased expression of H2AX protein
CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]; CYP3A7 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]		 CTD PMID:37788138 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]] CTD PMID:25981168 PMID:32890875 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression		 ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of HMOX1 mRNA
lapatinib metabolite results in increased expression of HMOX1 mRNA		 CTD PMID:26958860 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Jak2 Janus kinase 2 multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of JAK2 protein] CTD PMID:32890875 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases response to substance
multiple interactions		 ISO KRAS protein results in decreased susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]		 CTD PMID:28739874 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
decreases expression
decreases activity		 ISO ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]
lapatinib results in decreased phosphorylation of MAPK1 protein
lapatinib results in decreased expression of MAPK1 protein
lapatinib results in decreased activity of MAPK1 protein		 CTD PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk12 mitogen-activated protein kinase 12 multiple interactions ISO lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]] CTD PMID:28739874 NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
decreases expression
decreases activity		 ISO ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]
lapatinib results in decreased phosphorylation of MAPK3 protein
lapatinib results in decreased expression of MAPK3 protein
lapatinib results in decreased activity of MAPK3 protein		 CTD PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 multiple interactions
decreases expression		 ISO ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein] CTD PMID:25221644 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein] CTD PMID:26643609 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases activity		 ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein
lapatinib metabolite results in increased activity of NFE2L2 protein		 CTD PMID:26958860 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression		 ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of NQO1 mRNA
lapatinib metabolite results in increased expression of NQO1 mRNA		 CTD PMID:26958860 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of PARP1 protein]; [Lapatinib co-treated with bafilomycin A] results in increased cleavage of PARP1 protein; [Lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]] CTD PMID:25221644 PMID:25981168 PMID:29387217 PMID:32890875 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]] CTD PMID:32890875 PMID:33396024 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]] CTD PMID:32890875 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Ptpn3 protein tyrosine phosphatase, non-receptor type 3 multiple interactions ISO lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]] CTD PMID:28739874 NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:71,911,135...72,065,443 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of RAF1 protein] CTD PMID:32890875 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in decreased phosphorylation of RB1 protein] CTD PMID:32890875 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein] CTD PMID:26643609 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions
decreases response to substance		 ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of SNAI1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein]
SNAI1 protein results in decreased susceptibility to lapatinib		 CTD PMID:26643609 PMID:32890875 PMID:33396024 NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969 		JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]] CTD PMID:33396024 NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD1 mRNA CTD PMID:26958860 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression		 ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD2 mRNA
lapatinib metabolite results in increased expression of SOD2 mRNA		 CTD PMID:26958860 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of SOX2 protein CTD PMID:26643609 NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of SRC protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein] CTD PMID:26643609 PMID:32890875 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of STAT3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of STAT3 protein] CTD PMID:32890875 PMID:33396024 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases response to substance ISO TGFB1 protein results in decreased susceptibility to lapatinib CTD PMID:26643609 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Top1 DNA topoisomerase I decreases expression ISO Lapatinib results in decreased expression of TOP1 protein CTD PMID:37788138 NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623 		JBrowse link
G Top2a DNA topoisomerase II alpha decreases expression ISO Lapatinib results in decreased expression of TOP2A protein CTD PMID:37788138 NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 multiple interactions ISO Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]] CTD PMID:33396024 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 decreases activity
multiple interactions		 ISO Lapatinib results in decreased activity of UGT1A3 protein
[Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of obeticholic acid; [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of Ursodeoxycholic Acid		 CTD PMID:31299240 NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]] CTD PMID:32890875 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vim vimentin multiple interactions ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein] CTD PMID:26643609 PMID:32890875 PMID:33396024 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187 		JBrowse link
paroxetine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A increases export ISO ABCB1 protein results in increased export of Paroxetine CTD PMID:14550684 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Paroxetine results in increased expression of ABCC2 protein CTD PMID:12524417 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G App amyloid beta precursor protein multiple interactions ISO [Paroxetine binds to APP 5' UTR] which results in decreased secretion of APP protein modified form CTD PMID:15681799 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561 		JBrowse link
G Ar androgen receptor multiple interactions ISO Paroxetine binds to and results in decreased activity of AR protein CTD PMID:25752796 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Arc activity-regulated cytoskeleton-associated protein increases expression EXP Paroxetine results in increased expression of ARC mRNA CTD PMID:14580947 NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378 		JBrowse link
G Bdnf brain-derived neurotrophic factor increases expression ISO Paroxetine results in increased expression of BDNF mRNA; Paroxetine results in increased expression of BDNF protein CTD PMID:21301813 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity		 ISO Paroxetine results in increased activity of and results in increased cleavage of CASP3 protein
Paroxetine results in increased activity of CASP3 protein		 CTD PMID:17174998 PMID:28482088 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 increases activity ISO Paroxetine results in increased activity of CASP8 protein CTD PMID:28482088 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 increases activity ISO Paroxetine results in increased activity of CASP9 protein CTD PMID:28482088 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase multiple interactions
decreases activity		 ISO isoliquiritigenin inhibits the reaction [Paroxetine results in decreased activity of CAT protein]; Sildenafil Citrate inhibits the reaction [Paroxetine results in decreased activity of CAT protein] CTD PMID:36740106 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Chl1 cell adhesion molecule L1-like affects response to substance ISO CHL1 affects the susceptibility to Paroxetine CTD PMID:21332311 NCBI chr 4:136,291,504...136,505,830
Ensembl chr 4:136,291,463...136,503,265 		JBrowse link
G Cs citrate synthase increases activity EXP Paroxetine results in increased activity of CS protein CTD PMID:20347017 NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases activity ISO Paroxetine results in decreased activity of CYP19A1 protein CTD PMID:26162595 NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions
decreases activity		 ISO Paroxetine inhibits the reaction [CYP2B6 protein results in increased chemical synthesis of hydroxybupropion]; Paroxetine inhibits the reaction [CYP2B6 protein results in increased metabolism of Bupropion]
Paroxetine results in decreased activity of CYP2B6 protein		 CTD PMID:21915887 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 decreases metabolic processing
increases response to substance
increases metabolic processing
multiple interactions
decreases activity		 ISO CYP2D6 gene mutant form results in decreased metabolism of Paroxetine
CYP2D6 gene mutant form results in increased susceptibility to Paroxetine
CYP2D6 protein results in increased metabolism of Paroxetine
[Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased abundance of 4-hydroxy-N-desmethyltamoxifen; [Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased degradation of Metoprolol; [Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [Paroxetine results in decreased activity of CYP2D6 protein] which results in increased susceptibility to Metoprolol; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in decreased susceptibility to Debrisoquin]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in decreased susceptibility to Nortriptyline]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in increased abundance of 10-hydroxynortriptyline]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in increased abundance of Debrisoquin metabolite]; Paroxetine inhibits the reaction [CYP2D6 protein results in increased chemical synthesis of Dextrorphan]; Paroxetine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; Paroxetine inhibits the reaction [CYP2D6 protein results in increased oxidation of dimemorfan]		 CTD PMID:10470702 PMID:11673748 PMID:12173784 PMID:12378847 PMID:14639062 More... NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Dbh dopamine beta-hydroxylase increases response to substance ISO DBH protein results in increased susceptibility to Paroxetine CTD PMID:15148402 NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248 		JBrowse link
G Ddah1 dimethylarginine dimethylaminohydrolase 1 multiple interactions ISO Paroxetine inhibits the reaction [Manganese deficiency results in decreased expression of DDAH1 protein] CTD PMID:21312047 NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein CTD PMID:19662385 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Glud1 glutamate dehydrogenase 1 multiple interactions ISO Paroxetine inhibits the reaction [Manganese deficiency results in decreased expression of GLUD1 protein] CTD PMID:21312047 NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases activity
multiple interactions		 ISO Paroxetine results in increased activity of GPT protein
isoliquiritigenin inhibits the reaction [Paroxetine results in increased activity of GPT protein]; Sildenafil Citrate inhibits the reaction [Paroxetine results in increased activity of GPT protein]		 CTD PMID:36740106 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Hcrtr1 hypocretin receptor 1 increases expression ISO Paroxetine results in increased expression of HCRTR1 mRNA CTD PMID:21157932 NCBI chr 5:142,477,214...142,486,674
Ensembl chr 5:142,477,214...142,486,674 		JBrowse link
G Hcrtr2 hypocretin receptor 2 increases expression ISO Paroxetine results in increased expression of HCRTR2 mRNA CTD PMID:21157932 NCBI chr 8:76,989,834...77,105,953
Ensembl chr 8:76,989,834...77,105,893 		JBrowse link
G Hrh1 histamine receptor H 1 increases expression ISO Paroxetine results in increased expression of HRH1 mRNA CTD PMID:21157932 NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455 		JBrowse link
G Htr1b 5-hydroxytryptamine receptor 1B decreases expression EXP Paroxetine results in decreased expression of HTR1B mRNA CTD PMID:10861803 NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549 		JBrowse link
G Htr2a 5-hydroxytryptamine receptor 2A affects response to substance ISO HTR2A gene polymorphism affects the susceptibility to Paroxetine CTD PMID:17503984 NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928 		JBrowse link
G Htr2c 5-hydroxytryptamine receptor 2C multiple interactions ISO [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein; Paroxetine binds to and results in increased activity of HTR2C protein CTD PMID:19662385 NCBI chr  X:110,640,777...110,870,288
Ensembl chr  X:110,641,153...110,870,287 		JBrowse link
G Il10 interleukin 10 increases expression
multiple interactions		 ISO Paroxetine results in increased expression of IL10 mRNA; Paroxetine results in increased expression of IL10 protein
LY 215840 inhibits the reaction [Paroxetine results in increased expression of IL10 mRNA]; LY 215840 inhibits the reaction [Paroxetine results in increased expression of IL10 protein]		 CTD PMID:32020710 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il17a interleukin 17A multiple interactions
decreases expression		 ISO LY 215840 inhibits the reaction [Paroxetine results in decreased expression of IL17A protein] CTD PMID:32020710 NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889 		JBrowse link
G Il1b interleukin 1 beta affects expression ISO Paroxetine affects the expression of IL1B protein CTD PMID:32020710 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Ins2 insulin 2 multiple interactions EXP Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]; pyrazolanthrone inhibits the reaction [Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]] CTD PMID:17728140 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G Irs1 insulin receptor substrate 1 multiple interactions
decreases activity		 EXP Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]; pyrazolanthrone inhibits the reaction [Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]]
Paroxetine results in decreased activity of IRS1 protein		 CTD PMID:17728140 NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122 		JBrowse link
G Jak2 Janus kinase 2 multiple interactions
increases expression		 ISO LY 215840 promotes the reaction [Paroxetine results in increased expression of JAK2 mRNA] CTD PMID:32020710 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 multiple interactions ISO Paroxetine results in decreased activity of [KCNJ3 protein binds to KCNJ6 protein] CTD PMID:17072103 NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124 		JBrowse link
G Kcnj5 potassium inwardly-rectifying channel, subfamily J, member 5 multiple interactions ISO Paroxetine results in decreased activity of [KCNJ6 protein binds to KCNJ5 protein] CTD PMID:17072103 NCBI chr 8:30,724,923...30,753,083
Ensembl chr 8:30,724,925...30,753,518 		JBrowse link
G Kcnj6 potassium inwardly-rectifying channel, subfamily J, member 6 multiple interactions ISO Paroxetine results in decreased activity of [KCNJ3 protein binds to KCNJ6 protein]; Paroxetine results in decreased activity of [KCNJ6 protein binds to KCNJ5 protein]; Paroxetine results in decreased activity of [KCNJ6 protein binds to KCNJ6 protein] CTD PMID:17072103 NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein CTD PMID:19662385 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein CTD PMID:19662385 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases activity
multiple interactions		 EXP Paroxetine results in increased activity of MAPK8 protein
pyrazolanthrone inhibits the reaction [Paroxetine results in increased phosphorylation of and results in increased activity of MAPK8 protein]		 CTD PMID:17728140 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Pf4 platelet factor 4 decreases expression ISO Paroxetine results in decreased expression of PF4 protein CTD PMID:10770450 NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365 		JBrowse link
G Ppbp pro-platelet basic protein decreases expression ISO Paroxetine results in decreased expression of PPBP protein CTD PMID:10770450 NCBI chr14:17,302,326...17,303,130
Ensembl chr14:17,302,326...17,303,130 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression ISO Paroxetine results in decreased expression of PTGS2 mRNA; Paroxetine results in decreased expression of PTGS2 protein CTD PMID:17499975 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Paroxetine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Slc6a15 solute carrier family 6 member 15 multiple interactions ISO Paroxetine inhibits the reaction [Corticosterone results in decreased expression of SLC6A15 mRNA] CTD PMID:31344373 NCBI chr 7:38,553,055...38,607,239
Ensembl chr 7:38,553,196...38,607,239 		JBrowse link
G Slc6a4 solute carrier family 6 member 4 decreases expression
affects expression
multiple interactions		 ISO
EXP		 Paroxetine results in decreased expression of SLC6A4 mRNA
Paroxetine affects the expression of SLC6A4 mRNA
Paroxetine binds to and results in decreased activity of SLC6A4 protein		 CTD PMID:10575045 PMID:16055263 PMID:16272152 NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO Paroxetine inhibits the reaction [Manganese deficiency results in increased expression of SOD2 protein] CTD PMID:21312047 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases expression
multiple interactions
increases expression		 ISO Paroxetine results in decreased expression of STAT3 mRNA; Paroxetine results in decreased expression of STAT3 protein
LY 215840 promotes the reaction [Paroxetine results in increased expression of STAT3 mRNA]		 CTD PMID:17499975 PMID:32020710 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Tfap2a transcription factor AP-2 alpha increases expression ISO Paroxetine results in increased expression of TFAP2A protein CTD PMID:28844482 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507 		JBrowse link
G Tnf tumor necrosis factor decreases secretion
decreases expression
multiple interactions		 ISO Paroxetine results in decreased secretion of TNF protein
Paroxetine results in decreased expression of TNF protein
LY 215840 inhibits the reaction [Paroxetine results in decreased expression of TNF protein]		 CTD PMID:17499975 PMID:32020710 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Paroxetine results in increased expression of VEGFA mRNA CTD PMID:21301813 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vgf VGF nerve growth factor inducible increases expression ISO Paroxetine results in increased expression of VGF mRNA CTD PMID:21301813 NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19853
    role 19825
      application 19667
        NMR chemical shift reference compound 18040
          monofluorobenzene 104
            2-\{[2-(2-chlorophenyl)-2-hydroxyethyl]amino\}-N-[(2-fluorophenyl)methyl]acetamide 0
            Ro 320-1195 + 0
            fludiazepam 0
            lapatinib 66
            paroxetine + 50
Path 2
Term Annotations click to browse term
  CHEBI ontology 19853
    subatomic particle 19851
      composite particle 19851
        hadron 19851
          baryon 19851
            nucleon 19851
              atomic nucleus 19851
                atom 19851
                  main group element atom 19797
                    p-block element atom 19797
                      carbon group element atom 19738
                        carbon atom 19734
                          organic molecular entity 19734
                            organic molecule 19685
                              organic cyclic compound 19496
                                carbocyclic compound 18588
                                  benzenoid aromatic compound 18018
                                    benzenes 17884
                                      fluorobenzenes 6158
                                        monofluorobenzenes 4903
                                          monofluorobenzene 104
                                            2-\{[2-(2-chlorophenyl)-2-hydroxyethyl]amino\}-N-[(2-fluorophenyl)methyl]acetamide 0
                                            Ro 320-1195 + 0
                                            fludiazepam 0
                                            lapatinib 66
                                            paroxetine + 50
paths to the root